ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The present primary therapy of cervical intraepithelial neoplasia (CIN) grade 3 and
persistent CIN 2 represents conisation. Surgical treatment can cause perioperative
(infection, bleeding in in 5-10%) and postoperative (increased risk of preterm labor)
complications, as well as incomplete resections (20%) and risk of recurrence in 5-17%.
Imiquimod is an immunomodulating drug, that has been reported to be effective in human
papilloma virus-related disease, such as vulvar intraepithelial neoplasia (VIN), vaginal
intraepithelial neoplasia (VAIN), and anal intraepithelial neoplasia (AIN). The present
randomised, placebo controlled, double blind study evaluates the efficacy of a topical
treatment with imiquimod for 16 weeks in 60 patients with histologically confirmed CIN 2/3.